The autism spectrum disorder (ASD) market across the seven major markets (7MM) is projected to reach $2b in 2034 at a compound annual growth rate of 18.7%, according to a GlobalData report.
Pipeline Drugs Expected To Drive Growth
Expansion is linked to the expected launch of five late-stage pipeline therapies during the forecast period.
“In order of entry, these will be Curemark’s CM-AT/LUMINENZ-AT, Yamo Pharmaceuticals’ L1-79 (metyrosine), and MapLight Therapeutics’ ML-004 (zolmitriptan),” said Christie Wong, Managing Neurology Analyst at GlobalData.
These products are anticipated to generate approximately $1.7b in combined sales by 2034 across the 7MM, representing 8.4% of the ASD market.
Generic Use Remains a Limiting Factor
Despite projected growth, Wong noted that the persistent use of low-cost generic treatments may constrain market expansion.
The seven major markets include the US, France, Germany, Italy, Spain, the UK, and Japan.
Featured image credits: Freepik
For more stories like it, click the +Follow button at the top of this page to follow us.